CA2569707C - Modification du c-terminal de polypeptides - Google Patents

Modification du c-terminal de polypeptides Download PDF

Info

Publication number
CA2569707C
CA2569707C CA2569707A CA2569707A CA2569707C CA 2569707 C CA2569707 C CA 2569707C CA 2569707 A CA2569707 A CA 2569707A CA 2569707 A CA2569707 A CA 2569707A CA 2569707 C CA2569707 C CA 2569707C
Authority
CA
Canada
Prior art keywords
peptide
amino acid
trypsin
xaa2
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2569707A
Other languages
English (en)
Other versions
CA2569707A1 (fr
Inventor
Eva Hoess
Frank Bordusa
Rupert Herrmann
Hans-Dieter Jakubke
Wilhelm Tischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EUCODIS BIOSCIENCE GmbH
Original Assignee
EUCODIS BIOSCIENCE GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EUCODIS BIOSCIENCE GmbH filed Critical EUCODIS BIOSCIENCE GmbH
Publication of CA2569707A1 publication Critical patent/CA2569707A1/fr
Application granted granted Critical
Publication of CA2569707C publication Critical patent/CA2569707C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention a pour objet une trypsine transformée, comprenant une substitution d~acide aminé en position K60 comme en position D189, et au moins une autre substitution d~acide aminé par de l~histidine en position N143 ou en position E151. Ce mutant de trypsine possède un site de reconnaissance préférable comprenant les acides aminés Xaal -Xaaz His, au sein duquel Xaal est L, Y ou F et Xaa2 est R ou K. Cette invention a également pour objet un polypeptide artificiel comprenant un peptide cible ainsi que le site de reconnaissance précité, et un procédé de production de peptides cibles à C-terminal modifié à l~aide de cette trypsine transformée.
CA2569707A 2004-08-13 2005-08-12 Modification du c-terminal de polypeptides Active CA2569707C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04019237 2004-08-13
EP04019237.9 2004-08-13
PCT/EP2005/008809 WO2006015879A1 (fr) 2004-08-13 2005-08-12 Modification du c-terminal de polypeptides

Publications (2)

Publication Number Publication Date
CA2569707A1 CA2569707A1 (fr) 2006-02-16
CA2569707C true CA2569707C (fr) 2013-09-24

Family

ID=34926160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2569707A Active CA2569707C (fr) 2004-08-13 2005-08-12 Modification du c-terminal de polypeptides

Country Status (10)

Country Link
US (2) US20080064079A1 (fr)
EP (1) EP1778839B1 (fr)
JP (1) JP4538501B2 (fr)
CN (1) CN101010425B (fr)
AT (1) ATE400647T1 (fr)
CA (1) CA2569707C (fr)
DE (1) DE602005008071D1 (fr)
ES (1) ES2309785T3 (fr)
HK (1) HK1110888A1 (fr)
WO (1) WO2006015879A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
CN102482340B (zh) 2009-04-06 2015-05-13 诺沃—诺迪斯克有限公司 因子viii蛋白向血小板的靶向递送
WO2011058082A1 (fr) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Composition pharmaceutique comprenant un agoniste de glp-1 et de la méthionine
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
US9587006B2 (en) 2010-02-11 2017-03-07 Hoffmann-La Roche Inc. IGF-I poly (ethylene glycol) conjugates
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
PL3229828T3 (pl) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
EP3650541A1 (fr) 2018-11-08 2020-05-13 BioPharma Translationsinstitut Dessau Forschungs GmbH Mutant de trypsine pour la modification de polypeptides par les terminaux c et n
JP7360742B2 (ja) * 2018-12-19 2023-10-13 バイオファーマ トランスレーションズインスティテュート デッサウ フォルシュングス ゲーエムベーハー 酵素特性が改善したトリプシン変異体およびその使用ならびに基質の直交二重修飾のための方法
EP4073096A1 (fr) 2019-12-10 2022-10-19 Sanofi Procédé de formation d'un conjugué d'un sulfonamide et d'un polypeptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5580751A (en) * 1990-09-14 1996-12-03 Carlsberg A/S Process for the preparation of C-terminally amidated peptides
AU6171594A (en) 1993-02-04 1994-08-29 Genentech Inc. Serine protease variants having peptide ligase activity
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
CA2172145C (fr) 1994-07-25 2010-09-21 Hans-Peter Josel Complexes metalliques a linker charge
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
DE10049673A1 (de) * 2000-10-07 2002-04-25 Univ Leipzig Verfahren zur Herstellung von Peptiden, Peptidmimetika und Proteinen
CN1354253A (zh) * 2001-12-24 2002-06-19 南京医科大学 淡色库蚊胰蛋白酶基因

Also Published As

Publication number Publication date
CA2569707A1 (fr) 2006-02-16
WO2006015879A1 (fr) 2006-02-16
HK1110888A1 (en) 2008-07-25
ES2309785T3 (es) 2008-12-16
CN101010425A (zh) 2007-08-01
CN101010425B (zh) 2010-05-26
US20080064079A1 (en) 2008-03-13
US8927230B2 (en) 2015-01-06
EP1778839B1 (fr) 2008-07-09
JP2008508871A (ja) 2008-03-27
ATE400647T1 (de) 2008-07-15
JP4538501B2 (ja) 2010-09-08
US20130177940A1 (en) 2013-07-11
DE602005008071D1 (de) 2008-08-21
EP1778839A1 (fr) 2007-05-02

Similar Documents

Publication Publication Date Title
CA2569707C (fr) Modification du c-terminal de polypeptides
Choi et al. Recombinant enterokinase light chain with affinity tag: expression from Saccharomyces cerevisiae and its utilities in fusion protein technology
AU2008221532B2 (en) Cleavage of fusion proteins using Granzyme B protease
CN109439643B (zh) 一种新型赖氨酸特异性内切酶及其制备方法
CA2301698A1 (fr) Precurseurs zymogenes de proteases activables par voie autocatalytique et leur utilisation
EP3650541A1 (fr) Mutant de trypsine pour la modification de polypeptides par les terminaux c et n
čeřovský et al. Enzymatic semisynthesis of dicarba analogs of calcitonin
JP2002529101A (ja) ペプチドの酵素的アミド化
EP1730271A2 (fr) Enzyme et sa methode de preparation
JP3892397B2 (ja) ペプチド、ペプチド模倣物およびタンパク質を合成するための方法
EP1173572B1 (fr) Procede pour evacuer des polypeptides les residus d'alanine n-terminaux au moyen d'aminopeptidase d'aeromonas
Kubitzki et al. Application of immobilized bovine enterokinase in repetitive fusion protein cleavage for the production of mucin 1
US6428997B1 (en) Aminopeptidase derived from Bacillus licheniformis and process for preparation of natural type proteins
US6743600B1 (en) Method of removing N-terminal alanine residues from polypeptides with Aeromonas aminopeptidase
JP2004509973A (ja) ペプチドおよびタンパク質の選択的修飾方法
WO1994028018A2 (fr) Catalyseurs synthetiques a empechement sterique
PL213994B1 (pl) Mutant proteinazy SpIB i sposób otrzymywania mutanta proteinazy SpIB

Legal Events

Date Code Title Description
EEER Examination request